Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Pharmacol Res Perspect ; 8(6): e00688, 2020 12.
Artigo em Inglês | MEDLINE | ID: mdl-33280274

RESUMO

Functional neurological disorders (FNDs), which are sometimes also referred to as psychogenic neurological disorders or conversion disorder, are common disabling neuropsychiatric disorders with limited treatment options. FNDs can present with sensory and/or motor symptoms, and, though they may mimic other neurological conditions, they are thought to occur via mechanisms other than those related to identifiable structural neuropathology and, in many cases, appear to be triggered and sustained by recognizable psychological factors. There is intriguing preliminary evidence to support the use of psychedelic-assisted therapy in a growing number of psychiatric illnesses, including FNDs. We review the theoretical arguments for and against exploring psychedelic-assisted therapy as a treatment for FNDs. We also provide an in-depth discussion of prior published cases detailing the use of psychedelics for psychosomatic conditions, analyzing therapeutic outcomes from a contemporary neuroscientific vantage as informed by several recent neuroimaging studies on psychedelics and FNDs.


Assuntos
Alucinógenos/uso terapêutico , Transtornos Mentais/diagnóstico , Transtornos Mentais/tratamento farmacológico , Doenças do Sistema Nervoso/diagnóstico , Doenças do Sistema Nervoso/tratamento farmacológico , Adulto , Animais , Teorema de Bayes , Encéfalo/efeitos dos fármacos , Encéfalo/patologia , Criança , Distonia/diagnóstico , Distonia/tratamento farmacológico , Distonia/psicologia , Feminino , Alucinógenos/farmacologia , Humanos , Masculino , Transtornos Mentais/psicologia , Doenças do Sistema Nervoso/psicologia
2.
Bioorg Med Chem Lett ; 20(19): 5847-52, 2010 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-20727752

RESUMO

Initial high throughput screening efforts identified highly potent and selective kappa opioid receptor antagonist 3 (κ IC(50)=77 nM; µ:κ and δ:κ IC(50) ratios>400) which lacked CNS exposure in vivo. Modification of this scaffold resulted in development of a series of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides showing potent and selectivity κ antagonism as well as good brain exposure. Analog 6c (κ IC(50)=20 nM; µ:κ=36, δ:κ=415) was also shown to reverse κ-agonist induced rat diuresis in vivo.


Assuntos
Benzamidas/química , Receptores Opioides kappa/antagonistas & inibidores , Tropanos/química , Animais , Benzamidas/síntese química , Benzamidas/farmacocinética , Linhagem Celular Tumoral , Diurese/efeitos dos fármacos , Avaliação Pré-Clínica de Medicamentos , Ensaios de Triagem em Larga Escala , Humanos , Microssomos Hepáticos/metabolismo , Ratos , Receptores Opioides kappa/metabolismo , Relação Estrutura-Atividade , Tropanos/síntese química , Tropanos/farmacocinética
3.
Anal Chem ; 81(24): 9941-7, 2009 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-19904990

RESUMO

Here, complementary ion mobility/mass spectrometry (IM/MS) and ultrahigh-resolution Fourier transform ion cyclotron resonance (FTICR) MS analyses of light, medium, and heavy petroleum crude oils yielded distributions of the heteroatom-containing hydrocarbons, as well as multiple conformational classes. The IM/MS technique provides unique fingerprints for fast identification of signature conformational/compositional patterns, whereas FTICR MS analysis provides comprehensive heteroatom class distributions. IM/MS and FTICR MS results reveal an increase in compositional complexity in proceeding from light to medium to heavy crude oils. Inspection of the mobility results shows a high structural diversity for the C(n)H(h)XY (XY = N(1), S(1), N(1), O(1), NS, SO(1-2), NO(1-2), etc.) series, as well as a shift from planar to more compact three-dimensional structures with increasing mass.


Assuntos
Petróleo/análise , Análise de Fourier , Espectrometria de Massas
4.
Phytochemistry ; 67(9): 898-903, 2006 May.
Artigo em Inglês | MEDLINE | ID: mdl-16516254

RESUMO

Azetidine-2-carboxylic acid (L-Aze) is a toxic and teratogenic non-protein amino acid. In many species, including man, L-Aze is misincorporated into protein in place of proline, altering collagen, keratin, hemoglobin, and protein folding. In animal models of teratogenesis, it causes a wide range of malformations. The role of L-Aze in human disease has been unexplored, probably because the compound has not been associated with foods consumed by humans. Herein we report the presence of L-Aze in the garden or table beet (Beta vulgaris).


Assuntos
Ácido Azetidinocarboxílico/química , Beta vulgaris/química , Ácido Azetidinocarboxílico/análogos & derivados , Cromatografia Líquida , Espectrometria de Massas , Estrutura Molecular , Tubérculos/química , Prolina/análogos & derivados , Teratogênicos/química
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA